Development of Triamcinolone Acetonide Nanocrystals for Ocular Administration

Triamcinolone acetonide (TA) is a powerful anti-inflammatory drug used in the treatment of inflammatory ocular disorders; however, its poor aqueous solubility and ocular anatomical barriers hinder optimal treatment. The aim of this work was to obtain triamcinolone acetonide nanocrystals (TA-NC) to improve ocular corticosteroid therapy. Self-dispersible TA-NC were prepared by the bead milling technique followed by spray-drying, exhaustively characterized and then evaluated in vivo in an ocular model of endotoxin-induced uveitis (EIU). Self-dispersible TA-NC presented an average particle size of 257 ± 30 nm, a narrow size distribution and a zeta potential of −25 ± 3 mV, which remained unchanged for 120 days under storage conditions at 25 °C. In addition, SEM studies of the TA-NC showed uniform and spherical morphology, and FTIR and XRDP analyses indicated no apparent chemical and crystallinity changes. The subconjunctival administration of TA-NC in albino male white rabbits showed no clinical signs of ocular damage. In vivo studies proved that treatment with self-dispersible TA-NC alleviated the inflammatory response in the anterior chamber and iris in EUI rabbit eyes. Dispersible TA-NC are a promising approach to obtaining a novel nanometric TA formulation for ocular disorders.

[1]  B. Karasu,et al.  Efficacy of topical dexamethasone eye drops in preventing ocular inflammation and cystoid macular edema following uncomplicated cataract surgery with or without injection of a single dose perioperative subtenon triamcinolone acetonide , 2022, Cutaneous and ocular toxicology.

[2]  José Izo Santana da Silva de Jesus,et al.  Besifloxacin Nanocrystal: Towards an Innovative Ophthalmic Preparation , 2022, Pharmaceutics.

[3]  A. Silva,et al.  Customized cationic nanoemulsions loading triamcinolone acetonide for corneal neovascularization secondary to inflammatory processes. , 2022, International journal of pharmaceutics.

[4]  R. Donnelly,et al.  Nanosuspension-loaded dissolving bilayer microneedles for hydrophobic drug delivery to the posterior segment of the eye. , 2022, Biomaterials advances.

[5]  S. Palma,et al.  Nanocrystals as a master key to deliver hydrophobic drugs via multiple administration routes. , 2022, Journal of controlled release : official journal of the Controlled Release Society.

[6]  M. L. Formica,et al.  Manufacturing Techniques for Nanoparticles in Drug Delivery , 2021, Drug Delivery Using Nanomaterials.

[7]  A. Yousaf,et al.  Drug Delivery Using Nanomaterials , 2021 .

[8]  Moiz Ahmed,et al.  Safety and Efficacy of Suprachoroidal Injection of Triamcinolone in Treating Macular Edema Secondary to Noninfectious Uveitis , 2021, Cureus.

[9]  S. Ismail,et al.  Development of Triamcinolone Acetonide-Loaded Microemulsion as a Prospective Ophthalmic Delivery System for Treatment of Uveitis: In Vitro and In Vivo Evaluation , 2021, Pharmaceutics.

[10]  Makoto Nakamura,et al.  A case of panuveitis and retinal vasculitis associated with pembrolizumab therapy for metastatic lung cancer , 2021, American journal of ophthalmology case reports.

[11]  B. Pierscionek,et al.  Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives , 2020, Drug Delivery and Translational Research.

[12]  R. Faccio,et al.  Nanocrystals of Novel Valerolactam-Fenbendazole Hybrid with Improved in vitro Dissolution Performance , 2020, AAPS PharmSciTech.

[13]  C. Lanusse,et al.  Ricobendazole nanocrystals obtained by media milling and spray drying: pharmacokinetic comparison with the micronized form of the drug. , 2020, International journal of pharmaceutics.

[14]  J. Benoit,et al.  Triamcinolone acetonide-loaded lipid nanocapsules for ophthalmic applications. , 2020, International journal of pharmaceutics.

[15]  Vikram Patel,et al.  Application of Mechanistic Ocular Absorption Modeling and Simulation to Understand the Impact of Formulation Properties on Ophthalmic Bioavailability in Rabbits: a Case Study Using Dexamethasone Suspension , 2019, The AAPS Journal.

[16]  Haiyan Hu,et al.  Drug nanocrystals: Fabrication methods and promising therapeutic applications. , 2019, International journal of pharmaceutics.

[17]  E. Duh,et al.  Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[18]  Y. Qu,et al.  A more efficient ocular delivery system of triamcinolone acetonide as eye drop to the posterior segment of the eye , 2019, Drug delivery.

[19]  Qin-Mei Wang,et al.  Directing the nanoparticle formation by the combination with small molecular assembly and polymeric assembly for topical suppression of ocular inflammation , 2018, International journal of pharmaceutics.

[20]  Arturo Santos,et al.  Characterization and Pharmacokinetics of Triamcinolone Acetonide-Loaded Liposomes Topical Formulations for Vitreoretinal Drug Delivery. , 2018, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[21]  F. Otero-Espinar,et al.  Solid-state characterization of triamcinolone acetonide nanosuspensiones by X-ray spectroscopy, ATR Fourier transforms infrared spectroscopy and differential scanning calorimetry analysis , 2017, Data in brief.

[22]  F. Otero-Espinar,et al.  Improved release of triamcinolone acetonide from medicated soft contact lenses loaded with drug nanosuspensions. , 2017, International journal of pharmaceutics.

[23]  S. Lee,et al.  Development Considerations for Nanocrystal Drug Products , 2017, The AAPS Journal.

[24]  Jouni Hirvonen,et al.  Stabilizing Agents for Drug Nanocrystals: Effect on Bioavailability , 2016, Pharmaceutics.

[25]  S. Palma,et al.  Self-dispersible nanocrystals of albendazole produced by high pressure homogenization and spray-drying , 2016, Drug development and industrial pharmacy.

[26]  Yong Woo Lee,et al.  Triamcinolone acetonide nanoparticles incorporated in thermoreversible gels for age-related macular degeneration , 2016, Pharmaceutical development and technology.

[27]  P. Massin,et al.  INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA , 2015, Retina.

[28]  F. Boscia,et al.  Intravitreal Steroids for the Treatment of Retinal Diseases , 2014, TheScientificWorldJournal.

[29]  M. Ghahremani,et al.  Polymeric triamcinolone acetonide nanoparticles as a new alternative in the treatment of uveitis: in vitro and in vivo studies. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[30]  E. Souto,et al.  Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): in vitro and ex vivo studies. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[31]  Lei Gao,et al.  Drug nanocrystals: In vivo performances. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[32]  R. Müller,et al.  Twenty years of drug nanocrystals: where are we, and where do we go? , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[33]  O. Kul,et al.  A cannabinoid ligand, anandamide, exacerbates endotoxin-induced uveitis in rabbits. , 2011, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[34]  Jan Van Humbeeck,et al.  Solubility increases associated with crystalline drug nanoparticles: methodologies and significance. , 2010, Molecular pharmaceutics.

[35]  V. Chikán,et al.  Quantized Ostwald Ripening of Colloidal Nanoparticles , 2010 .

[36]  Michael D. Ober,et al.  Intravitreal triamcinolone acetonide and intraocular pressure. , 2004, American journal of ophthalmology.

[37]  P. Wiedemann,et al.  Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells , 2001, Graefe's Archive for Clinical and Experimental Ophthalmology.

[38]  A. Noyes,et al.  The rate of solution of solid substances in their own solutions , 1897 .